The global automated blood processing equipment market was valued at around US$ 44,050.0 Million at the end of 2021. The market is projected to register a 6.68% CAGR and top a valuation of US$ 89,823.4 Million by 2032.
The increasing prevalence of chronic disorders such as cancer, COPD, Alzheimer’s disease, and other is the key factor responsible for boosting the market growth.
The collection and processing of whole blood samples using automated blood processing equipment. Whole blood is primarily used as a source for making different blood components, including platelets, plasma, red blood cells (RBCs), white blood cells (WBCs), and others.
The automated blood processing equipment assists in the creation of numerous blood components that are mostly utilized for blood transfusions and other uses. The main advantages of automated blood processing equipment are reduced human interaction with low contamination risks and a shorter processing time by fewer processing stages. Hospitals and blood banks place a high priority on maximising throughput without adding to the workload on the lab, advancing patient care, and improving laboratory productivity with automated blood processing technology.
Compared to conventional blood processing equipment, automated equipment produces result more quickly and reliably, facilitating diagnosis and treatment while shortening wait times in emergency rooms.
| Attributes | Details |
|---|---|
| Automated Blood Processing Equipment Market Value in 2021 | US$ 44,050.0 Million |
| Automated Blood Processing Equipment Market Value in 2032 | US$ 89,823.4 Million |
| Automated Blood Processing Equipment Market CAGR (2022 to 2032) | 6.68% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The primary drivers of the market expansion over the forecast period include an increase in demand for blood components of safer and higher quality, rising rates of chronic diseases, vigorous campaigning for blood donation programmes, and rising healthcare expenditures.
The growth of donor screening test kits and technological improvements both significantly contribute to the rising demand for automated blood equipment. Changes in the way blood is collected and the progressive switch from manual to automated blood processing are all expected to have a positive impact on market expansion.
In order to integrate the market in developing economies, the leading manufacturers in the market are also expanding the value chain. The need for automated blood processing equipment is being driven by rising healthcare expenditures and government investments in healthcare facilities in the majority of developed countries.
The automated blood processing equipment market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America dominated the regional automated blood processing equipment market due to developed healthcare infrastructure, government support, and access to cutting-edge blood collecting facilities.
Western Europe is the second-largest market for automated blood processing equipment, due to an increase in blood donation facilities and blood transfusion facilities, which drive demand. The prevalence of chronic diseases and the volume of surgical procedures are other major drivers of the demand for pathogen-free blood and its components, which in turn drives up demand for automated blood equipment.
Principal Consultant
Immucor, JMS Singapore Pte Ltd, MOELCA, LMB Technologie GmbH, Delcon SRL., Baxter Healthcare, Macopharma, Grifols, Beckman Coulter, Inc, Fresenius Kabi AG, and Terumo Corporation.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 6.68% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, Volume in Units, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segment Covered | Product Type, End-User, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Spain, Italy, Russia, BENELUX, China, Japan, South Korea, India, Malaysia, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, North Africa, Turkey |
| Key Players | Immucor; JMS Singapore Pte Ltd; MOELCA; LMB Technologie GmbH; Delcon SRL.; Baxter Healthcare; Macopharma; Grifols; Beckman Coulter, Inc; Fresenius Kabi AG; Terumo Corporation |
| Customization | Available Upon Request |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global automated blood processing equipment Market is anticipated to register a CAGR of 6.68% during the forecast period.
Immucor, JMS Singapore Pte Ltd, MOELCA, LMB Technologie GmbH, Delcon SRL., Baxter Healthcare, Macopharma, Grifols, Beckman Coulter, Inc, Fresenius Kabi AG, and Terumo Corporation, among others are some prominent automated blood processing equipment market players.
Explore Healthcare Insights
View Reports
Automated Blood Processing Equipment Market
